Explore the efficacy and safety of targeted small molecule drug TYK2 inhibitors in combination with and without calcipotriol betamethasone for the treatment of adult moderate to severe plaque psoriasis.

Start Date01 Nov 2024

Sponsor / Collaborator-

CTR20223222 / CompletedPhase 3

一项在中国稳定性斑块状银屑病成人受试者中比较LEO 90100和得肤宝 ®软膏治疗4周的有效性和安全性的III期、随机、研究者设盲、活性药物对照、平行分组、多中心试验

[Translation] A Phase III, randomized, investigator-blinded, active-controlled, parallel-group, multicenter trial comparing the efficacy and safety of LEO 90100 and Depo-Perot® Ointment for 4 weeks in Chinese adult subjects with stable plaque psoriasis

主要目的：评价LEO 90100与得肤宝®软膏相比对稳定性斑块状银屑病严重程度和范围的有效性。次要目的：评价LEO 90100与得肤宝®软膏相比治疗稳定性斑块状银屑病的安全性。

[Translation]

Primary objective: To evaluate the effectiveness of LEO 90100 compared with Defubain® Ointment on the severity and extent of stable plaque psoriasis. Secondary objective: To evaluate the safety of LEO 90100 compared with Defubain® Ointment in the treatment of stable plaque psoriasis.

Start Date21 Jun 2023

Sponsor / Collaborator

LEO Laboratories Ltd.

[+2]

NCT05919082 / CompletedPhase 3

A Phase 3, Randomised, Investigator-blind, Active-controlled, Parallel Group, Multicentre Trial Comparing the Efficacy and Safety of 4-weeks Treatment With LEO 90100 and Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis

This study is conducted to assess the efficacy and safety of LEO 90100 when used on the body for the treatment of stable plaque psoriasis in native adult Chinese subjects, compared to Daivobet® ointment.

Start Date21 Jun 2023

Sponsor / Collaborator

Leo Pharma, Inc.

100 Clinical Results associated with Betamethasone Dipropionate/Calcipotriene

100 Translational Medicine associated with Betamethasone Dipropionate/Calcipotriene

100 Patents (Medical) associated with Betamethasone Dipropionate/Calcipotriene

Literatures (Medical) associated with Betamethasone Dipropionate/Calcipotriene

01 Mar 2024·Dermatology and Therapy

Improvements in Plaque Psoriasis Associated with Calcipotriol/Betamethasone Aerosol Foam Treatment: A Post Hoc Analysis of Non-interventional Studies and Clinical Experience

Article

Author: Krogager Eeg, Martin ; Jablonski Bernasconi, Marie Y ; Ratzinger, Gudrun ; Campanati, Anna ; Gerdes, Sascha ; Halioua, Bruno ; Pesiridis, Georgios ; Lazaridou, Elizabeth

INTRODUCTIONPlaque psoriasis is a chronic relapsing inflammatory skin disease that is associated with extensive disease burden that often requires long-term therapy. Treatment of psoriasis with 4 weeks of the aerosol foam formulation of calcipotriol/betamethasone dipropionate (Cal/BD; Enstilar®, LEO Pharma) has been demonstrated to be effective, well tolerated, and associated with high patient satisfaction. Cal/BD foam is approved as a first-line treatment in multiple countries, where several non-interventional studies (NIS) have corroborated the beneficial efficacy and safety profiles determined in the randomized clinical trials. Heterogenicity in these NIS, however, prevents the use of a data pooling strategy for comparisons of effectiveness outcomes across different patient populations.METHODSTherefore, here, we report on a post hoc analysis of effectiveness data consolidated from six prospective NIS to discern any differences in improvement in signs and symptoms of psoriasis attributable to Cal/BD foam treatment across the countries. In addition, we provide real-world experience of clinicians with Cal/BD foam treatment, factoring in changes in usage since these NIS were performed in their local markets.RESULTSThis post hoc analysis of Cal/BD foam NIS brings together data outside of randomized clinical trials from six countries to provide real-world evidence in 1388 patients showing that 4 weeks of Cal/BD foam is an effective and safe treatment option with quick onset of action for patients with psoriasis.CONCLUSIONThese results show that regardless of NIS location, Cal/BD foam remains a well-tolerated, efficacious option for patient care that could be used as a first-line topical therapy for mild-to-severe psoriasis.

31 Dec 2023·Journal of Dermatological Treatment

Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics

Article

Author: Zhang, Xiaomei ; Yao, Danni ; Lu, Chuanjian ; Cui, Jingwen ; Yu, Xiaobo ; Deng, Hao ; Ye, Shuyan ; Han, Ling ; Deng, Jingwen ; Yu, Jingjie ; Yan, Yuhong

BACKGROUNDPsoriasis is a chronic skin disease, and topical sequential therapy with a combination of calcipotriol and calcipotriol betamethasone is currently approved topical treatment. However, the exact mechanism by which this treatment regimen relieves psoriasis is unknown.METHODWe assembled a cohort of 65 psoriasis patients and divided post-treatment cohort into responder group and non-responder group according to the Psoriasis Area Severity Index (PASI) score after 12-week treatment. We measured the expression levels of proteins in collected 130 serum samples using our in-depth proteomics platform with a data-independent acquisition mass spectrometer and antibody microarray. We performed bioinformatics analyses of the biologic processes and signaling pathways that were changed in the responder group and constructed a proteomics landscape of psoriasis pathogenesis response to treatment. We then validated the biomarkers of disease severity in an independent cohort of 88 samples using an enzyme-linked immunosorbent assay.RESULTSWe first identified 174 differentially expressed proteins (DEPs) for comparative analysis of proteins between responders and non-responders at baseline (p < 0.05). Then pathway analysis showed that the responders focused more on signaling molecules and interaction, complement and coagulation cascades, whereas the non-responders more on signal transduction and IL-17 signaling pathways. We further identified four candidate biomarkers (COLEC11, C1QA, BNC2, ITIH4) response to treatment. We also found 125 DEPs (p < 0.05) after treatment compared with before treatment in responder group. Pathway analysis showed an enrichment in pathways related to complement and coagulation cascades, phagosome, ECM-receptor interaction, cholesterol metabolism, vitamin digestion and absorption. CD14 was validated as potential biomarkers for the disease severity of psoriasis and treatment targets.CONCLUSIONIn this work, we analyzed the response to topical sequential therapy and finally identified four biomarkers. Additionally, we found that topical sequential therapy may alleviate psoriasis by regulating lipid metabolism and modulating the immune response by affecting the complement activation process.

01 Nov 2023·European review for medical and pharmacological sciences

The role of the foam formulation in improving psoriasis treatment acceptability: a real-life experience and a literature review.

Review

Author: Martella, A ; Papa, S ; Giovene, G L ; Gasparini, S

BACKGROUNDTopical therapies represent the first-line treatment for mild-to-moderate psoriasis. Among various topical options, the fixed-dose combination of calcipotriene (Cal) and betamethasone dipropionate (BD) foam (Enstilar®, LEO Pharma, Ballerup, Denmark) showed superior efficacy to Cal and BD monotherapy and ointment and gel formulations. In addition, the Cal/BD foam is the only topical treatment allowed for either reactive treatment of relapse or twice-weekly maintenance use. Since treatment acceptability is crucial to optimize adherence, this paper presents a case series from a multicenter experience using the Cal/BD foam, to further characterize the use of this therapeutic approach. In addition, a narrative review of studies evaluating the acceptability of the Cal/BD foam, even compared with other formulations, is provided.CASE SERIESThe case series involved adult patients with mild-to-moderate psoriasis treated with the Cal/BD foam from October 2021 to June 2022. A clinical and dermoscopic evaluation of plaques was provided for all patients. Data from the clinical practice report complete clinical resolution of plaques in most patients after 4 weeks of active treatment with the Cal/BD foam, and the dermoscopic clearance after a maximum of 8 weeks. Full adherence to treatment was also reported. Literature evidence suggests that the Cal/BD foam is easy to apply and presents high cosmetic acceptance, rapid onset of action, high efficacy, optimal safety, and a high patient preference. The high satisfaction obtained with Cal/BD foam suggests that this formulation is better accepted than others.CONCLUSIONSThe Cal/BD foam represents a valuable approach for managing mild-to-moderate psoriasis, both in short and long-term treatment.

News (Medical) associated with Betamethasone Dipropionate/Calcipotriene

15 Nov 2024

·www.prnewswire.com

Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada

MALVERN, Pa., Nov. 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream (calcipotriene and betamethasone dipropionate) in Canada through Endo's subsidiary Paladin Pharma Inc. "We look forward to working with MC2 to make Wynzora® Cream available to Canadians who suffer from plaque psoriasis," said Livio Di Francesco, Vice President and General Manager of Paladin. "If approved by Health Canada, Wynzora® Cream's unique formulation and clinical profile will offer patients a new treatment option designed for convenience of use in daily routines." "Paladin has an experienced and dedicated team, and we're pleased to work with them to introduce Wynzora® Cream in Canada," said Jesper J. Lange, Chief Executive Officer, MC2 Therapeutics. "The agreement aligns with our strategy to make Wynzora® Cream available to as many patients suffering from plaque psoriasis as possible globally." Wynzora® Cream was approved in the US by the FDA on July 20, 2020 and launched in Europe on February 18, 2022. About Wynzora® Cream Wynzora® Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, including scalp psoriasis, in adults. Its dual mode of action is targeting the hallmark cytokines IL-23 and IL-17A/F immune axis and TNF-α expression in a single product. Wynzora® Cream is uniquely enabled by MC2's formulation and drug delivery system PAD Technology™, allowing a convenient-to-use aqueous formulation. About Endo and Paladin Pharma Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at or connect with us on LinkedIn. Paladin Pharma Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing, medical and sales organization that has helped it evolve into one of Canada's leading specialty pharmaceutical companies. Paladin is an operating company of Endo, Inc. For more information, visit . About MC2 Therapeutics () MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation. Its pioneering approach in immunology is anchored in a deep understanding of skin biology, clinical expertise and cross-silo thinking. Besides Wynzora® Cream, MC2 has a pipeline that includes two first-in-class drug candidates, both in Phase 2 clinical development. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements including, but not limited to, the statements by Messrs. Di Francesco and Lange and any statements relating to product development and commercialization, treatment options and therapies, regulatory approval, efficacy and product availability. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, unfavorable or delayed regulatory review, uncertainties in and the timing for regulatory approval, changes in competitive, market or regulatory conditions, and consumer and physician acceptance of current and new products. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in Endo's press releases and in its public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-Q and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A. SOURCE Endo, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalLicense out/inPhase 2

30 Sep 2024

·www.pharmaceutical-technology.com

LEO Pharma announces Enstilar NDA submission for plaque psoriasis in China

The review process is set for completion in H1 2026. Credit: Hriana via Shutterstock. Leo Pharma has submitted a New Drug Application (NDA) to China’s National Medical Products Administration for Enstilar, targeting the treatment of adult patients with plaque psoriasis. Enstilar is an aerosol spray foam combining calcipotriol and betamethasone, designed to improve upon the existing Daivobet ointment, which is currently a standard treatment in China. The submission follows a series of milestones for LEO Pharma in the EU and the US, with China potentially becoming the largest market for Enstilar. The NDA is supported by a Phase III trial involving 604 adult Chinese subjects with stable plaque psoriasis. This trial showed Enstilar to be superior to Daivobet ointment, achieving both primary and secondary endpoints. See Also: FDA approves PureTech’s KarXT to treat schizophrenia in adults FDA greenlights Regeneron’s Dupixent for the treatment of COPD The Center for Drug Evaluation (CDE) in China will now validate and fully evaluate the NDA. The regulatory review process is anticipated to be completed in the first half (H1) of 2026. LEO Pharma China general manager Byron Yin said: “LEO Pharma strives to enhance patient care and elevate quality of life for those living with complex skin conditions like plaque psoriasis. “Today’s submission is a crucial step towards offering a much-needed new treatment option in our region, in addition to the existing portfolio offering from LEO Pharma China.” Enstilar is already indicated in the EU for up to four weeks of treatment for psoriasis vulgaris in adults, with suitable candidates eligible for long-term maintenance. Recently, the European Commission authorised Leo Pharma’s Anzupgo cream for treating adults with moderate to severe chronic hand eczema .

Phase 3NDAClinical ResultDrug Approval

27 Sep 2024

·www.businesswire.com

LEO Pharma Submits New Drug Application for Enstilar® for Adults with Plaque Psoriasis in China

BALLERUP, Denmark--( BUSINESS WIRE )-- NOT INTENDED FOR DISTRIBUTION IN THE UK LEO Pharma A/S, a global leader in medical dermatology, has today announced its submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA) for Enstilar ® (LEO 90100) to treat adult patients living with plaque psoriasis. Following a week of significant LEO Pharma treatment and data milestones in the EU and the U.S., today’s news of the NDA submission in China is the latest example of LEO Pharma’s global strategy in action across medical dermatology. If approved, China would join 50 other markets in the world to be approved to bring Enstilar to patients, and would be the largest country to date. Enstilar ® , a calcipotriol/betamethasone cutaneous foam, is an improved formulation of Daivobet ® ointment, which is one of the current standard treatment options in China for adults living with plaque psoriasis. 4 Both Daivobet ointment and Enstilar are LEO Pharma products. “ LEO Pharma strives to enhance patient care and elevate quality of life for those living with complex skin conditions like plaque psoriasis ,” said Byron Yin, General Manager for LEO Pharma, China. “ Today’s submission is a crucial step towards offering a much-needed new treatment option in our region, in addition to the existing portfolio offering from LEO Pharma China.” “ Today’s submission of our NDA for Enstilar is a testament to LEO Pharma’s truly global outlook and ambition in advancing dermatology, following on from a week of milestones across both the EU and U.S.” said Becki Morison, Executive Vice President, Global Product Strategy & International Operations for LEO Pharma. “ China is a key market for LEO Pharma, with dermatology growing rapidly in the country and our revenue steadily increasing through a strong performance from our team. We will continue to leverage our extensive dermatology expertise to enhance the treatments we can provide in the region, unwavering in our goal to provide support to those in China that need it most.” The NDA submission is supported by results from a phase 3 trial comparing the efficacy and safety of a once daily application with Enstilar and Daivobet ointment after 4 weeks of treatment in adult Chinese subjects with stable plaque psoriasis (N=604). 1,2 The trial achieved its primary and secondary endpoints, with Enstilar demonstrating superiority to Daivobet ointment. 2 “ The trial showed the potential that Enstilar has to improve the quality of life for millions of Chinese patients living with plaque psoriasis,” said Professor Zhang Jianzhong from Peking University People's Hospital, lead investigator of the phase 3 Enstilar trial. “ Through today’s milestone, we take a step towards new treatment options for the millions that live with plaque psoriasis in the near future.” Following the Enstilar submission, the Centre for Drug Evaluation (CDE) will validate the filing, before the full evaluation of the NDA is conducted by the CDE. The regulatory review process is expected to conclude in the first half of 2026. About Enstilar ® Enstilar ® is an aerosol spray foam containing calcipotriol monohydrate 50 mcg/g and betamethasone dipropionate 0.5 mg/g. In the EU, it is indicated for the treatment of psoriasis vulgaris in adults for up to 4 weeks. Patients who have responded at 4 weeks’ treatment using Enstilar once daily are suitable for long-term maintenance treatment. 4-7 About Psoriasis Psoriasis is a chronic, systemic inflammatory disease that primarily affects the skin in 125 million people worldwide. 8,9 Psoriasis is the result of skin barrier cell proliferation and the activation of cytokines (a family of proteins involved in immune responses) that cause inflammation. 10 About 80% to 90% of patients are affected by plaque psoriasis, the most common clinical form of psoriasis. 11 The symptoms of plaque psoriasis are itchy or painful raised scaly and inflamed plaques. Plaques may appear anywhere on the body, but often appear on the scalp, knees, elbows and torso. 11 About LEO Pharma LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion. References ClinicalTrials.gov. National Library of Medicine (U.S.). A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis. Identifier: NCT05919082. https://clinicaltrials.gov/study/NCT05919082 . LEO Pharma Press Release. LEO Pharma Announces Topline Results of Phase 3 Trial in China for Enstilar® (LEO 90100) Demonstrating Superiority in Adult Chinese Subjects With Stable Plaque Psoriasis. Published: May 04, 2024. Last accessed: Sep 25, 2024. Available at: https://www.businesswire.com/news/home/20240507292614/en/LEO-Pharma-Announces-Topline-Results-of-Phase-3-Trial-in-China-for-Enstilar%C2%AE-LEO-90100-Demonstrating-Superiority-in-Adult-Chinese-Subjects-With-Stable-Plaque-Psoriasis . Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663-667. Zhang, XJ et al., Chin J Dermatol, July 2023, Vol. 56, No. 7, Guideline for the diagnosis and treatment of psoriasis in China (2023 edition) Enstilar ® EU Summary of Product Characteristics July 2022. Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study. J Dermatolog Treat. 2016;27(2):120-127. Leonardi C, et al. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris—a Randomized Phase III Study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468-1477. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643-659. National Psoriasis Foundation. Psoriasis Statistics. Last updated: Dec 21, 2022. Last accessed: Sep 25, 2024. Available at: https://www.psoriasis.org/content/statistics . Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645-653. National Psoriasis Foundation. Plaque Psoriasis. Last updated: Feb 08, 2024. Last accessed: Sep 25, 2024. Available at: https://www.psoriasis.org/plaque/ . MAT-76612 September 2024

Phase 3Clinical ResultPhase 2NDAImmunotherapy

100 Deals associated with Betamethasone Dipropionate/Calcipotriene

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	D05AX52	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Psoriasis of scalp	GB	Almirall SA	29 Jul 2021
Psoriasis	CH	LEO Pharma A/S	04 Sep 2008
Plaque psoriasis	US	LEO Pharma A/S	09 May 2008
Psoriasis vulgaris	US	LEO Pharma A/S	09 Jan 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plaque psoriasis	NDA/BLA	CN	LEO Pharma A/S	27 Sep 2024
Allergic skin reaction	Phase 2	US	MC2 Therapeutics Ltd.	13 Feb 2019
Dermatitis, Phototoxic	Phase 2	JP	Leo Pharma, Inc.	01 Dec 2010
Psoriasis vulgaris	Phase 2	US	Leo Pharma, Inc.	01 Sep 2010
Scalp Dermatoses	Phase 2	CN	Leo Pharma, Inc.	01 Sep 2010
Arthritis, Psoriatic	Phase 2	FR	Leo Pharma, Inc.	01 Jan 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05919082 (NEWS) Manual	Phase 3	Plaque psoriasis	604	LEO 90100	rhkqmidpsb(xnlowypgye) = Enstilar®在主要终点上相较于得肤宝®（卡泊三醇倍他米松软膏）表现出优效性 beseeaseee (yanwebsfzi ) Met View more	Positive	08 May 2024
				得肤宝
NCT04440371 (Pubmed \| J Dermatolog Treat)	Not Applicable	Vitiligo	-	Calcipotriol/betamethasone dipropionate cream	dzosdfieot(ylykugjznr) = yzvlhvniki osiytakiod (xxbpnnjfkr )	Negative	31 Dec 2023
				Tacrolimus 0.1% ointment	dzosdfieot(ylykugjznr) = luyazhpkrl osiytakiod (xxbpnnjfkr )
NCT03308799 (Biospace) Manual	Phase 3	Skin Pigmentation	-	Calcipotriene+Betamethasone Dipropionate/Calcipotriene (Patients with skin of color (Fitzpatrick IV-VI))	(zdrosbvhhj) = gozymudqgz vsdddcvkzu (zqehgqhate ) View more	Positive	15 Sep 2022
Pubmed Manual	Not Applicable	Psoriasis vulgaris	166	Calcipotriene+LEO90100	(ulfhbssxet) = eimxkislcg kemivrobvz (wghgyhkbwr, 3.0) View more	Positive	18 Jul 2022
NCT02668692 (CTgov)	Phase 3	Psoriasis vulgaris	213	LEO 80185 gel	unjnwgfmem(fgqvolbetj) = gqbuzjdzmr ioqmybgbzp (jqzwlgalup, iipcwoguxs - oxpcnrqorj) View more	-	27 Jul 2021
NCT03819218 (CTgov)	Phase 2	Psoriasis vulgaris	7	MC2-01 cream	mvoazlwaeb(psbufbjjur) = suiujxnszn cocliekzbr (xdokugkwpz, hsmhcnvlbn - irpsnnxqzz) View more	-	21 Feb 2021
NCT03506477 (CTgov)	Phase 4	Plaque psoriasis	25	Enstilar® foam (Enstilar® Foam)	eijwfuaxvl(ntdqwlvvle) = xjjmjoxsql eshhqtkhhm (uxijeqdrhx, sfjbmkezee - ezaejecjpw) View more	-	20 Jan 2021
				Vehicle Foam (Vehicle Foam)	eijwfuaxvl(ntdqwlvvle) = sxhlcykgpw eshhqtkhhm (uxijeqdrhx, zykmnxrbop - swinbdnpet) View more
NCT03806790 (CTgov)	Phase 3	Psoriasis vulgaris	182	LEO 90100 foam (LEO 90100 Foam)	bkhxqkpteg(isapsdnucn) = mtelsbptfl qpetycsvnu (tuhiycefvv, avfqadobrw - fejjojbjie) View more	-	16 Dec 2020
				Dovobet® ointment (Dovobet® Ointment)	bkhxqkpteg(isapsdnucn) = ggjzroyynt qpetycsvnu (tuhiycefvv, fegciwzgyd - kwmqkdjlqr) View more
NCT03802344 (CTgov)	Phase 3	Psoriasis vulgaris	498	MC2-01 cream (MC2-01 Cream)	tvfynqayaa(yrraxvmipe) = injkxwiodl xahstljpbx (rkkhrbkwow, pcivuorndq - rcquktclhn) View more	-	27 Nov 2020
				Cal/BDP combination (Cal/BDP Combination)	tvfynqayaa(yrraxvmipe) = fjlbtkwoxr xahstljpbx (rkkhrbkwow, bzapkuuszr - boztwsubaq) View more
NCT03848871 (CTgov)	Phase 4	Plaque psoriasis	20	Enstilar	ihmhqhbgsu(snzeeralys) = befikpndzu ktuajiovzz (rgqzrjbdcy, vqgdawtwcf - ecobkfwfqg) View more	-	26 Aug 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis